NDAORALGRANULE
Approved
Apr 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
E.E.S. (erythromycin ethylsuccinate) by R-Pharm US is mechanism of action erythromycin acts by inhibition of protein synthesis by binding 50s ribosomal subunits of susceptible organisms. Approved for the following infections caused by chlamydia trachomatis : conjunctivitis of the newborn, pneumonia of infancy, urogenital infections during pregnancy and 8 more indications. First approved in 1965.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
E.E.S. (erythromycin ethylsuccinate) is an oral macrolide antibiotic approved in 1965 that treats bacterial and chlamydial infections including neonatal conjunctivitis, pneumonia, urogenital infections, and nongonococcal urethritis. It works by inhibiting bacterial protein synthesis via 50S ribosomal subunit binding.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting focus on cost-containment and generic transition management rather than growth initiatives.
Mechanism of Action
Mechanism of Action Erythromycin acts by inhibition of protein synthesis by binding 50S ribosomal subunits of susceptible organisms. It does not affect nucleic acid synthesis.
Worked on E.E.S. at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.